Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;34(6):736-742.
doi: 10.1111/fcp.12558. Epub 2020 Apr 27.

Drug-induced vitiligo: a case/non-case study in Vigibase® , the WHO pharmacovigilance database

Norah Anthony #  1 , Delphine Bourneau-Martin #  1 , Sarah Ghamrawi  1 , Laurence Lagarce  1 , Marina Babin  1 , Marie Briet  1   2   3
Affiliations

Drug-induced vitiligo: a case/non-case study in Vigibase® , the WHO pharmacovigilance database

Norah Anthony et al. Fundam Clin Pharmacol. 2020 Dec.

Abstract

Vitiligo is a common depigmenting disorder ensuing the loss of epidermal melanocytes. It is a multifactorial disease with immunological, genetic and environmental factors including drug exposure. The purpose of the study was to investigate the drugs and therapeutic subclasses associated with vitiligo occurrence reported in VigiBase® , the WHO pharmacovigilance database. A case/non-case study was carried out by defining cases as vitiligo reports and non-cases as all other reports. The reporting odds ratio (ROR) was calculated for the 'suspected' drugs and drug classes according to ATC level 4. During the study period, 741 cases of vitiligo were registered. Mean age was 49 ± 20 years. The disproportionality analysis showed an association between vitiligo and pembrolizumab (ROR 116.9, 95% Confidence Interval (CI) 94.8, 144.3), nivolumab (ROR 22.6, 95% CI 15.8, 32.4), ipilimumab (ROR 41.7, 95% CI 25.0, 69.7), imiquimod (ROR 152.8, 95% CI 103.0, 226.7), adalimumab (ROR 3.8, 95% CI 2.5,5.8), infliximab (ROR 2.6, 95% CI 1.65, 4.01), alemtuzumab (ROR 27.8, 95% CI 17.6, 43.9), and ustekinumab (ROR 9.3, 95% CI 5.6, 15.6). Concerning the pharmacological classes ATC level 4, a significant association was found with monoclonal antibodies, interferons, selective immunosuppressants, TNF-alpha inhibitors, interleukin inhibitors, and topical antivirals. This study confirmed the expected associations between vitiligo and immune checkpoint inhibitors and strengthened the emerging signal about the association between vitiligo and imiquimod, TNF-alpha inhibitors and interferons. New signals were shown with selective immunosuppressants including alemtuzumab and interleukin inhibitors.

Keywords: Vitiligo; antibodies monoclonal; interferons; pharmacovigilance.

PubMed Disclaimer

References

REFERENCES

    1. Taïeb A., Picardo M. Clinical practice. Vitiligo. N. Engl. J. Med. (2009) 360 160-169.
    1. Ezzedine K., Eleftheriadou V., Whitton M., van Geel N. Vitiligo. Lancet Lond. Engl. (2015) 386 74-84.
    1. Gey A., Diallo A., Seneschal J. et al. Autoimmune thyroid disease in vitiligo: multivariate analysis indicates intricate pathomechanisms. Br. J. Dermatol. (2013) 168 756-761.
    1. Richmond J.M., Frisoli M.L., Harris J.E. Innate immune mechanisms in vitiligo: danger from within. Curr. Opin. Immunol. (2013) 25 676-682.
    1. van den Boorn J.G., Konijnenberg D., Dellemijn T.A.M. et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J. Invest. Dermatol. (2009) 129 2220-2232.